- Home
- ZENV vs PROK Comparison
ZENV vs PROK Comparison
Compare ZENV & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- PROK
- Stock Information
- Founded
- ZENV 2005
- PROK 2015
- Country
- ZENV Brazil
- PROK United States
- Employees
- ZENV N/A
- PROK N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- PROK Health Care
- Exchange
- ZENV Nasdaq
- PROK Nasdaq
- Market Cap
- ZENV 79.2M
- PROK 85.5M
- IPO Year
- ZENV 2021
- PROK N/A
- Fundamental
- Price
- ZENV $1.49
- PROK $0.65
- Analyst Decision
- ZENV
- PROK Hold
- Analyst Count
- ZENV 0
- PROK 3
- Target Price
- ZENV N/A
- PROK $3.50
- AVG Volume (30 Days)
- ZENV 87.2K
- PROK 1.7M
- Earning Date
- ZENV 07-02-2025
- PROK 08-08-2025
- Dividend Yield
- ZENV N/A
- PROK N/A
- EPS Growth
- ZENV N/A
- PROK N/A
- EPS
- ZENV N/A
- PROK N/A
- Revenue
- ZENV $181,911,572.00
- PROK $306,000.00
- Revenue This Year
- ZENV $8.58
- PROK $54.34
- Revenue Next Year
- ZENV $8.83
- PROK N/A
- P/E Ratio
- ZENV N/A
- PROK N/A
- Revenue Growth
- ZENV 23.99
- PROK N/A
- 52 Week Low
- ZENV $1.02
- PROK $0.46
- 52 Week High
- ZENV $3.03
- PROK $2.59
- Technical
- Relative Strength Index (RSI)
- ZENV 44.62
- PROK 43.63
- Support Level
- ZENV $1.45
- PROK $0.54
- Resistance Level
- ZENV $1.59
- PROK $0.90
- Average True Range (ATR)
- ZENV 0.16
- PROK 0.13
- MACD
- ZENV -0.01
- PROK -0.02
- Stochastic Oscillator
- ZENV 16.96
- PROK 20.25
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.